Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Carey Hwang et al.|The Lancet HIV|2018Cited by 145
Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19Hannes Vietzen, Elisabeth Puchhammer‐Stöckl, Alexander Zoufaly et al.|Genetics in Medicine|2021Cited by 138
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Christine Katlama, Jean‐Michel Molina et al.|The Lancet HIV|2023Cited by 31
High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19Hannes Vietzen, Elisabeth Puchhammer‐Stöckl, Vera Danklmaier et al.|Genetics in Medicine|2022Cited by 24
Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndromeMax Augustin, Clara Lehmann, Ferdinand Heyn et al.|Frontiers in Medicine|2023Cited by 12